X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs DIVIS LABORATORIES - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD DIVIS LABORATORIES BIOCON LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 36.7 18.4 199.5% View Chart
P/BV x 4.9 4.0 122.5% View Chart
Dividend Yield % 1.5 1.6 97.5%  

Financials

 BIOCON LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    BIOCON LTD
Mar-16
DIVIS LABORATORIES
Mar-16
BIOCON LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs4962,484 20.0%   
Low Rs397918 43.2%   
Sales per share (Unadj.) Rs174.3142.3 122.5%  
Earnings per share (Unadj.) Rs44.841.9 107.0%  
Cash flow per share (Unadj.) Rs56.946.3 122.8%  
Dividends per share (Unadj.) Rs5.0010.00 50.0%  
Dividend yield (eoy) %1.10.6 190.6%  
Book value per share (Unadj.) Rs202.8161.5 125.5%  
Shares outstanding (eoy) m200.00265.47 75.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.612.0 21.4%   
Avg P/E ratio x10.040.6 24.5%  
P/CF ratio (eoy) x7.836.7 21.4%  
Price / Book Value ratio x2.210.5 20.9%  
Dividend payout %11.223.9 46.7%   
Avg Mkt Cap Rs m89,220451,525 19.8%   
No. of employees `0004.43.7 119.1%   
Total wages/salary Rs m6,3633,649 174.4%   
Avg. sales/employee Rs Th7,894.510,184.4 77.5%   
Avg. wages/employee Rs Th1,441.2984.1 146.4%   
Avg. net profit/employee Rs Th2,029.72,998.5 67.7%   
INCOME DATA
Net Sales Rs m34,85437,764 92.3%  
Other income Rs m845848 99.6%   
Total revenues Rs m35,69938,612 92.5%   
Gross profit Rs m8,20014,138 58.0%  
Depreciation Rs m2,4231,182 205.0%   
Interest Rs m10223 439.7%   
Profit before tax Rs m6,52013,781 47.3%   
Minority Interest Rs m-7440-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5,7540-   
Tax Rs m2,5692,662 96.5%   
Profit after tax Rs m8,96111,119 80.6%  
Gross profit margin %23.537.4 62.8%  
Effective tax rate %39.419.3 203.9%   
Net profit margin %25.729.4 87.3%  
BALANCE SHEET DATA
Current assets Rs m39,93230,947 129.0%   
Current liabilities Rs m16,2765,195 313.3%   
Net working cap to sales %67.968.2 99.5%  
Current ratio x2.56.0 41.2%  
Inventory Days Days54117 45.9%  
Debtors Days Days8685 101.2%  
Net fixed assets Rs m39,10117,027 229.6%   
Share capital Rs m1,000531 188.4%   
"Free" reserves Rs m38,59142,341 91.1%   
Net worth Rs m40,55642,877 94.6%   
Long term debt Rs m20,7245 440,936.2%   
Total assets Rs m84,81649,684 170.7%  
Interest coverage x64.9595.0 10.9%   
Debt to equity ratio x0.50 466,170.7%  
Sales to assets ratio x0.40.8 54.1%   
Return on assets %10.722.4 47.6%  
Return on equity %22.125.9 85.2%  
Return on capital %19.032.2 59.0%  
Exports to sales %30.785.3 36.1%   
Imports to sales %20.422.9 89.0%   
Exports (fob) Rs m10,71732,198 33.3%   
Imports (cif) Rs m7,1058,654 82.1%   
Fx inflow Rs m11,78932,270 36.5%   
Fx outflow Rs m8,3938,775 95.7%   
Net fx Rs m3,39623,496 14.5%   
CASH FLOW
From Operations Rs m5,26410,379 50.7%  
From Investments Rs m-9,540-4,135 230.7%  
From Financial Activity Rs m10,867-6,241 -174.1%  
Net Cashflow Rs m6,5913 199,727.3%  

Share Holding

Indian Promoters % 40.4 52.0 77.7%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 11.8 71.2%  
FIIs % 10.7 19.0 56.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.2 115.7%  
Shareholders   109,995 31,796 345.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   TORRENT PHARMA  NATCO PHARMA  ELDER PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bank Stocks Witness Selling(01:30 pm)

After opening the day on a flat note, the Indian share markets have reversed the trend and are currently trading above the dotted line.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Aug 17, 2017 03:37 PM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS